Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals
Journal: Journal of Veterinary Science & Medicine (Vol.4, No. 1)Publication Date: 2016-06-30
Authors : Emily Faulkner; Megan Hamrick; Mark A. Brown;
Page : 1-2
Keywords : Generics; Biosimilars; Ethics; Pharmaceuticals; Prices;
Abstract
Recent price hikes by pharmaceutical companies underscore the importance of competition in an industry that often sets prices according to what the market will bear. A steady pipeline of generics and biosimilars is the surest check to the rising prices of drugs and biologics. However, this pipeline has regularly failed to keep pace with the expiration of name-brands' periods of exclusivity. Thus, we must rely, in part, upon good ethical practices when it comes to the pricing of life-saving therapeutics.
Other Latest Articles
- A Review on Zinc Sulphide Nanoparticles: From Synthesis, Properties to Applications
- Efficacy and Toxicity Assessment of Different Clinically Used Small Molecular Tyrosine Kinase Inhibitors by Computational Molecular Docking Method
- PROJECT ON MANAGEMENT OF THE NATURAL AND TERRITORIAL COMPLEX OF THE RIVERS OF THE BASIN OF THE GULF OF FINLAND
- Metabolomics: How it can be applied in Infectious Medicine?
- A Pilot Study of Oxaloacetate 100 mg Capsules in Parkinson’s Disease Patients
Last modified: 2016-12-22 19:00:52